Detection of Multidrug Resistance in Mycobacterium tuberculosis

ABSTRACT We developed a DNA sequencing-based method to detect mutations in the genome of drug-resistant Mycobacterium tuberculosis. Drug resistance in M. tuberculosis is caused by mutations in restricted regions of the genome. Eight genome regions associated with drug resistance, including rpoB for rifampin (RIF), katG and the mabA (fabG1)-inhA promoter for isoniazid (INH), embB for ethambutol (EMB), pncA for pyrazinamide (PZA), rpsL and rrs for streptomycin (STR), and gyrA for levofloxacin, were amplified simultaneously by PCR, and the DNA sequences were determined. It took 6.5 h to complete all procedures. Among the 138 clinical isolates tested, 55 were resistant to at least one drug. Thirty-four of 38 INH-resistant isolates (89.5%), 28 of 28 RIF-resistant isolates (100%), 15 of 18 EMB-resistant isolates (83.3%), 18 of 30 STR-resistant isolates (60%), and 17 of 17 PZA-resistant isolates (100%) had mutations related to specific drug resistance. Eighteen of these mutations had not been reported previously. These novel mutations include one in rpoB, eight in katG, one in the mabA-inhA regulatory region, two in embB, five in pncA, and one in rrs. Escherichia coli isolates expressing individually five of the eight katG mutations showed loss of catalase and INH oxidation activities, and isolates carrying any of the five pncA mutations showed no pyrazinamidase activity, indicating that these mutations are associated with INH and PZA resistance, respectively. Our sequencing-based method was also useful for testing sputa from tuberculosis patients and for screening of mutations in Mycobacterium bovis. In conclusion, our new method is useful for rapid detection of multiple-drug-resistant M. tuberculosis and for identifying novel mutations in drug-resistant M. tuberculosis.

[1]  R. Gilman,et al.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis , 1997, Antimicrobial agents and chemotherapy.

[2]  I. H. Lim,et al.  Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore , 1999, Antimicrobial Agents and Chemotherapy.

[3]  G. Alangaden,et al.  Mechanism of Resistance to Amikacin and Kanamycin in Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[4]  A. Telenti,et al.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria , 1997, Antimicrobial agents and chemotherapy.

[5]  T. Kirikae,et al.  Characterization of a Trinucleotide Repeat Sequence (CGG)5 and Potential Use in Restriction Fragment Length Polymorphism Typing of Mycobacterium tuberculosis , 2004, Journal of Clinical Microbiology.

[6]  M. Makino,et al.  Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. , 1998, Journal of clinical microbiology.

[7]  H. Billman-Jacobe,et al.  Molecular Characterization of Isoniazid-Resistant Mycobacterium tuberculosis Isolates Collected in Australia , 2005, Antimicrobial Agents and Chemotherapy.

[8]  D. Rouse,et al.  Site‐directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase–peroxidase activities and isoniazid resistance , 1996, Molecular microbiology.

[9]  A. Telenti,et al.  Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations , 1997, Antimicrobial agents and chemotherapy.

[10]  M. Visser,et al.  Molecular Detection of Antimicrobial Resistance , 2001, Clinical Microbiology Reviews.

[11]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[12]  J. T. Crawford,et al.  The rpoB gene of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[13]  G. Bai,et al.  Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. , 1995, The Journal of infectious diseases.

[14]  R. Magliozzo,et al.  Characterization of the W321F mutant of Mycobacterium tuberculosis catalase–peroxidase KatG , 2002, Protein science : a publication of the Protein Society.

[15]  A. van der Ende,et al.  The Susceptibility of Mycobacterium tuberculosis to Isoniazid and the Arg→Leu Mutation at Codon 463 of katG Are Not Associated , 2001, Journal of Clinical Microbiology.

[16]  J. Musser,et al.  Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities , 1996, Antimicrobial agents and chemotherapy.

[17]  L. Wayne,et al.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria. , 1974, The American review of respiratory disease.

[18]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[19]  Julian Parkhill,et al.  The complete genome sequence of Mycobacterium bovis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Jacobs,et al.  Molecular genetics of mycobacteria. , 2000 .

[21]  M. Miller,et al.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay , 1995, Journal of clinical microbiology.

[22]  G. Bai,et al.  The rpsL gene and streptomycin resistance in single and multiple drug‐resistant strains of Mycobacterium tuberculosis , 1993, Molecular microbiology.

[23]  E. Böttger,et al.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.

[24]  A. Telenti,et al.  The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol , 1997, Nature Medicine.

[25]  N. L. Goodman,et al.  Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens , 1983, Journal of clinical microbiology.

[26]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[27]  J. Musser,et al.  Isoniazid Activation Defects in Recombinant Mycobacterium tuberculosis Catalase-Peroxidase (KatG) Mutants Evident in InhA Inhibitor Production , 2003, Antimicrobial Agents and Chemotherapy.

[28]  L. Heifets,et al.  Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. , 1989, The American review of respiratory disease.

[29]  A. Telenti,et al.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations , 1994, Antimicrobial Agents and Chemotherapy.

[30]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[31]  J. Musser,et al.  Antimicrobial agent resistance in mycobacteria: molecular genetic insights , 1995, Clinical microbiology reviews.

[32]  S. Cole,et al.  Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.

[33]  P. Loewen,et al.  Molecular characterization of three mutations in katG affecting the activity of hydroperoxidase I of Escherichia coli. , 1990, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[34]  S. Girotto,et al.  Rapid Formation of Compound II and a Tyrosyl Radical in the Y229F Mutant of Mycobacterium tuberculosis Catalase-peroxidase Disrupts Catalase but Not Peroxidase Function* , 2003, Journal of Biological Chemistry.

[35]  Alimuddin Zumla,et al.  Multidrug-resistant tuberculosis--can the tide be turned? , 2001, The Lancet. Infectious diseases.

[36]  J. Sacchettini,et al.  The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. , 1998, Microbiology.

[37]  Teresa Quitugua,et al.  Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[38]  Anthony Maxwell,et al.  Interaction between DNA Gyrase and Quinolones: Effects of Alanine Mutations at GyrA Subunit Residues Ser83and Asp87 , 2001, Antimicrobial Agents and Chemotherapy.

[39]  Audrey S. M. Teo,et al.  Novel Mutations in ndh in Isoniazid-Resistant Mycobacterium tuberculosisIsolates , 2001, Antimicrobial Agents and Chemotherapy.